DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Translate

Hypereosinophilic syndrome

Author: Dr Fiona Larsen, Dermatology registrar, Greenlane Hospital, Auckland, New Zealand, 2005.


toc-icon
Table of contents
arrow-right-small

What is hypereosinophilic syndrome?

Hypereosinophilic syndrome is a rare condition defined by three criteria:

  1. A blood count shows increased numbers of eosinophils (greater than 1500 eosinophils/uL) persisting for at least 6 months
  2. Signs and symptoms due to involvement of several internal organs
  3. No evidence of parasites, allergy, or other known causes of an elevated eosinophil count.

The condition largely occurs in males (90%), typically at middle age.

Some patients have an underlying blood disorder present, most commonly a form of leukaemia. Leukaemia may also be diagnosed up to 9-12 years after the initial diagnosis of hypereosinophilic syndrome.

What does it look like?

Hypereosinophilic syndrome usually presents with fever, weight loss, fatigue, and rash.

A rash is present in over 50% of patients, but is non-specific in appearance. Most commonly, red swollen itchy nodules (lumps) have been described. It can also resemble urticaria (hives).

An enlarged liver and spleen is often present indicating liver and spleen involvement. The lungs, kidneys, heart and nervous system can be affected.

Hypereosinophilic syndrome

Investigations

An elevated peripheral blood eosinophil count is found on a full blood count test.

A skin biopsy often reveals an infiltrate of eosinophils.

Treatment

Approximately 70% of patients respond to high dose oral corticosteroid therapy with oral prednisone, with the eosinophilia returning to normal levels. Other treatments include interferon alpha, hydroxyurea, PUVA therapy and recently imatinib mesylate (Gleevec®) in selected patients. The overall 5-year survival for patients with hypereosinophilic syndrome is 80% and the cause of death is usually heart failure.

 

 

Related information

Sign up to the newsletter